CN104491415A - Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine - Google Patents

Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine Download PDF

Info

Publication number
CN104491415A
CN104491415A CN201510000466.6A CN201510000466A CN104491415A CN 104491415 A CN104491415 A CN 104491415A CN 201510000466 A CN201510000466 A CN 201510000466A CN 104491415 A CN104491415 A CN 104491415A
Authority
CN
China
Prior art keywords
parts
radix
medicine
rhizoma
chronic obstructive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510000466.6A
Other languages
Chinese (zh)
Inventor
宫巧俐
张苗海
侯晓群
张向农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Municipal Hospital
Original Assignee
Qingdao Municipal Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Municipal Hospital filed Critical Qingdao Municipal Hospital
Priority to CN201510000466.6A priority Critical patent/CN104491415A/en
Publication of CN104491415A publication Critical patent/CN104491415A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a medicine for treating chronic obstructive pulmonary disease during stable period and a preparation method of the medicine. The medicine is prepared from astragalus membranaceus, polygonatum kingianum, radix glehniae, aster, earthworm, inula flower, cortex albiziae, salviae miltiorrhizae, ligusticum wallichii, bombyx batryticatus, poria cocos, ginger processed pinellia, honey-fried licorice root, rhizoma atractylodis macrocephalae, epimedium and rhodiola rosea. The medicine has the effects of strengthening spleen, freeing lung, tonifying kidney, regulating qi, eliminating phlegm, removing stasis, relieving cough and asthma, resolving depression and calming, can be used for achieving the effect of treating both symptoms and root cause of the chronic obstructive pulmonary disease during stable period, improving lung functions, relieving clinical symptoms and improving the living quality and prognosis of patients in the chronic obstructive pulmonary disease during stable period. The medicine composition has remarkable effect and no side effect on treatment of the chronic obstructive pulmonary disease during stable period.

Description

A kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease and preparation method thereof
Technical field
The present invention relates to a kind of Chinese medicine formula, a kind of medicine for the treatment of chronic obstructive pulmonary disease, especially a kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease.
Background technology
Chronic obstructive pulmonary disease (chronic obstructivepulmonarydisease, COPD) be a kind of disease with flow limitation feature, flow limitation is not exclusively reversible, develops in Progressive symmetric erythrokeratodermia, reacts relevant with the abnormal inflammatory of pulmonary to harmful gas or deleterious particle.COPD mainly involves lungs, but also can cause the ill effect of whole body (or lung is outer).The main clinical manifestation of COPD is cough, expectoration, dyspnea, in its course of disease, often occur acute exacerbation, and acute exacerbation is the principal element promoting continuing disease progress.COPD belongs to the category of Chinese medicine " pulmonary distension ".Ancient Chinese medicine doctor, to the description of " pulmonary distension " primary symptom, is mainly summarized as chest swollen full, feeling of distension and oppression as plug, dyspnea and cough due to adverse raising of QI, abundant expectoration, and agitation, cardiopalmus etc., namely with " cough, expectorant, breathe heavily, swollen, swollen, the stasis of blood " six words are for principal character.At chronic obstructive pulmonary disease (COPD) Acute Exacerbation Period, though treatment by Chinese herbs effect is rapid not as good as Western medicine, but at stable phase, adopt Chinese medicine to have obvious advantage, show and improve symptom, minimizing acute exacerbation, the raising aspect such as motor capacity and quality of life.
The basic goal of COPD stable phase treatment is to prevent acute exacerbation, improves ADL, prevents and treats or slow down the continuation deterioration of cardio-pulmonary function.Doctor trained in Western medicine is mainly bronchodilator, glucocorticoid, smoking cessation, training and long term oxygen therapy etc. in the treatment of COPD stable phase, but these therapies can not improve the change of blood samples of patients " dense, glutinous, solidifying, poly-", microcirculation disturbance can not be improved, and the evidence that the medicine of enhancing immunity (as vaccine, immunomodulator etc.) still lacks abundance supports that it is in the generally application of COPD stable phase patient, and fundamentally can not solve COPD patient acute exacerbation and pulmonary function continuous decrease problem repeatedly.Large quantifier elimination shows that the treatment of Chinese medicine to COPD stable phase has obvious effect, for prevention PD with repeatedly increase the weight of, improve quality of life aspect and have positive role.Research confirms that the advantage of Chinese traditional treatment COPD stable phase is: the immunologic function regulating body, regulates body endocrinosity, improve microcirculation, improve body nutriture etc.
Chinese medicine thinks that COPD stable phase exists the deficiency of lung, spleen, kidney, and lung qi virtual loss, then weakened defensive QI subject to heresy and invade, therefore the heresy of six climate exopathogens attacks lung repeatedly, bring out the generation of primary disease; If pneumonopathy and spleen, son consumption mother-qi, then dysfunction of the spleen in transportation, stomach is received and is not good for, body malnutrition, respiratory muscle fatigue, and the state of an illness is difficult to rehabilitation; Sick deficiency of the lung affecting the kidney for a long time, the not main gas of lung, then there is asthma, dyspnea increase the weight of in failure of the kidney in receiving QI, dynamic then more very, the decline of pulmonary function Progressive symmetric erythrokeratodermia; Lung and heart pulse-phase lead to, and lung qi is assisted a ruler in governing a country heart and run blood vessels, and lung qi prolonged deficiency controls joint dereliction of duty, then limitation of movement, quality of life decline.And lung, spleen, suffer from a deficiency of the kidney cause the change of body fluid raw, transfer and evaporate exception, be then easy to the turbid retention of expectorant, the turbid lung that accumulates of expectorant, lung qi stasis, can not administer regulate painstaking effort follows row, it is the stasis of blood that heart arteries and veins loses smooth then blood stagnation, simulataneous insufficiency and excessive, repeatedly vicious cycle.Liver controlling conveyance and dispersion, liver rises lung and falls and coordinate to be the important step of whole body QI movement being in harmonious way, and it is the hinge of ascending or descending movement of vital Qi discrepancy that spleen rises that stomach falls, and the catharsis of liver directly affects the transporting of spleen and being received of stomach; Irritability stasis directly can cause the generation of expectorant, the stasis of blood.Often there is serious anxio-depressive disorders in COPD patient in addition, and easily occur anxiety, anxiety, fear and Negative Emotional and the atypical behavior such as apologetic, dejected, frustrated, desperate, and these diseases are all relevant with the liver failing to maintain the normal flow of QI.In sum, COPD stable phase pathologic feature is " deficiency in origin and excess in superficiality ", and deficiency in origin is main, has mark concurrently real.Deficiency in origin mainly refers to lung, spleen, kidney and has a guilty conscience; Mark is real refers to the turbid and blood stasis of the stagnation of QI, expectorant, and both can influence each other.Therefore, control and work as strengthening the body resistance, support lung the kidney invigorating based on spleen invigorating, hold concurrently to get rid of evils, with activating QI to eliminate phlegm blood stasis dispelling, regulate the environment of body, the defense mechanism of excitating organism, the homeostasis of enhancing body, to promote Rehabilitation, prevents from repeatedly increasing the weight of.
Summary of the invention
New and effectively safe be applicable to medicine for the treatment of stable phase of chronic obstructive pulmonary disease and preparation method thereof for obtaining, the present inventor through a large amount of further investigations, after having paid sufficient creative work, has completed the present invention to this.
For the understanding of the traditional Chinese medical science to chronic obstructive pulmonary disease etiology and pathogenesis, the present invention adopts spleen invigorating to support lung the kidney invigorating, holds concurrently and carries out Coryza Treated by Syndrome Differentiation with the medicine of activating QI to eliminate phlegm blood stasis dispelling.
The present invention relates to a kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease, comprise the Radix Astragali, Rhizoma Polygonati, Radix Glehniae, Radix Asteris, Pheretima, Flos Inulae, Cortex Albiziae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Bombyx Batryticatus (parched), Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae Preparata, the Rhizoma Atractylodis Macrocephalae, Herba Epimedii and Radix Rhodiolae.
Exemplify as one is exemplary, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
Radix Astragali 20-50 part, Rhizoma Polygonati 15-30 part, Radix Glehniae 15-30 part, Radix Asteris 12-20 part, Pheretima 12-20 part, Flos Inulae 6-15 part, Cortex Albiziae 15-30 part, Radix Salviae Miltiorrhizae 10-20 part, Rhizoma Chuanxiong 10-20 part, Bombyx Batryticatus (parched) 6-12 part, Poria 10-20 part, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 6-15 part Radix Glycyrrhizae Preparata 6-12 part, Rhizoma Atractylodis Macrocephalae 10-30 part, Herba Epimedii 10-20 part, Radix Rhodiolae 10-30 part.
Further, medicine of the present invention has optimum ratio to be:
The Radix Astragali 30 parts, Rhizoma Polygonati 20 parts, Radix Glehniae 15 parts, Radix Asteris 15 parts, Pheretima 15 parts, Flos Inulae 10 parts, Cortex Albiziae 20 parts, Radix Salviae Miltiorrhizae 15 parts, Rhizoma Chuanxiong 15 parts, Bombyx Batryticatus (parched) 10 parts, 15 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10 parts, Radix Glycyrrhizae Preparata 10 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Epimedii 15 parts, Radix Rhodiolae 20 parts.
A kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease as above, its preparation method is: 1), according to described weight portion take the Radix Astragali, after Rhizoma Polygonati, Radix Glehniae, Radix Asteris, Flos Inulae, Cortex Albiziae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae Preparata, the Rhizoma Atractylodis Macrocephalae, Herba Epimedii, Radix Rhodiolae clear water soak 2 hours, add the decocting 2.5 ~ 3.5 hours of 13 ~ 17 times of weight, filter centrifugation removes slag, and is condensed into clear paste; 2), take Pheretima, the Bombyx Batryticatus (parched) of corresponding weight portion, be broken into fine powder; 3), by step 2) fine powder, uniform stirring is in step 1) in gained clear paste, mix homogeneously, obtains described medicine.
Preferably, step 1) in for adding the decocting 3 hours of 15 times of weight.
Described medicine can add customary adjuvant, conveniently technique, makes tablet, capsule, powder, pill, granule, unguentum or oral liquid.
Taboo: during medication, prohibit pickle, smoke, pungent, wine, life, food cool, really up to the mark, fried food, beverage.
Wherein, the action and efficacy of major pharmaceutical component is:
The Radix Astragali: sweet, temperature, returns spleen, lung meridian.Tonifying Qi and lifting yang, benefit defends consolidating superficial resistance, promoting pus discharge and tissue regeneration strengthening, diuretic detumescent.
Rhizoma Polygonati: sweet is flat.Return spleen, lung, kidney channel.Nourishing YIN and moistening the lung, the kidney invigorating and essence nourishing, invigorating the spleen and replenishing QI.
Radix Glehniae: sweet, is slightly cold.Attach to the lung and stomach meridians.Clearing lung and nourishing yin, reinforcing stomach reg fluid.
Radix Asteris: Radix Asteris: bitter, sweet, tepor.Return lung meridian.Nourishing the lung to keep the adverse QI downward, stopping coughing and removing phlegm.
Pheretima: salty, cold.Return liver, spleen, urinary bladder channel.Clearing heat for calming endogenous wind, clearing lung, relieving asthma, clearing away heat and promoting diuresis.
Flos Inulae: bitter, pungent, salty, tepor.Return lung, spleen, stomach, large intestine channel.The expectorant of therapeutic method to keep the adverse QI flowing downwards row water, stopping nausea and vomiting by lowering the adverse flow of QI removes.
Cortex Albiziae: sweet, flat.GUIXIN, Liver Channel.To calm the nerves resolving depression, promoting blood circulation and detumescence.
Radix Salviae Miltiorrhizae: bitter, be slightly cold.GUIXIN, pericardium, Liver Channel.Blood circulation promoting and blood stasis dispelling, removing heat from blood eliminating carbuncle, clear away heart-fire relieving restlessness, nourishing blood to tranquillize the mind.
Rhizoma Chuanxiong: pungent, temperature.Return liver, gallbladder, pericardium channel.Blood-activating and qi-promoting, wind-expelling pain-stopping.
Bombyx Batryticatus (parched): salty, pungent is flat.Endogenous wind stopping relieving convulsion, wind-expelling pain-stopping, detoxicating and resolving stagnation of pathogens, dispelling wind for relieving itching.
Poria: sweet, light is flat.Promoting diuresis to eliminate damp pathogen, invigorating spleen and reinforcing stomach, mind tranquilizing and the heart calming.
Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens): pungent, temperature.Return spleen, stomach, lung meridian.Drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.
Radix Glycyrrhizae Preparata: sweet is flat.GUIXIN, lung, spleen, stomach warp.Invigorating the spleen and replenishing QI, nourishing the lung to arrest cough, heat-clearing and toxic substances removing, relieving spasm to stop pain, relaxes the property of medicine, is in harmonious proportion hundred medicines.
Herba Epimedii: pungent, sweet, temperature.Return liver, kidney channel.Kidney-replenishing, bone and muscle strengthening, expelling wind and removing dampness.
The Rhizoma Atractylodis Macrocephalae: sweet, bitter, temperature.Return spleen, stomach warp.Invigorating the spleen and benefiting QI, dampness diuretic, strengthening superficial resistance to stop perspiration.
Radix Rhodiolae: bitter, sweet, flat, return lung, heart channel.Benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma.Tibetan medicine's Four-Volume Medical Code carries: property is put down, heat clearing away, nourishing vigour, and promoting the circulation of QI nourishes blood, and energy the kidney invigorating, the main whole body is weak.
Wherein, the present invention is directed to the understanding of the traditional Chinese medical science to chronic obstructive pulmonary disease mechanism, spleen invigorating is supported lung the kidney invigorating, the pharmaceutical science compatibilities such as activating QI to eliminate phlegm blood stasis dispelling, our medicine supports lung the kidney invigorating based on spleen invigorating, and the kidney invigorating of spleen invigorating lung qi dispersing is with strengthening the body resistance, activating QI to eliminate phlegm blood stasis dispelling takes stopgap measures to get rid of evils, hold concurrently with relieving cough and asthma, resolving stagnation for tranquilization, be used for the treatment of COPD stable phase, there is good curative effect.
Beneficial effect of the present invention:
In conjunction with pharmacology and the property of medicine of above-mentioned raw materials medicine, through large quantifier elimination and Clinical Treatment Test repeatedly, develop medicine of the present invention, have the kidney invigorating of spleen invigorating lung qi dispersing with righting, activating QI to eliminate phlegm blood stasis dispelling, to get rid of evils, is held concurrently with relieving cough and asthma, resolving stagnation for tranquilization effect.Medicine of the present invention can reach the effect to stable phase of chronic obstructive pulmonary disease treating both the principal and secondary aspects of a disease, improves pulmonary function, alleviates clinical symptoms, and improves patients with chronic obstructive pulmonary disease quality of life and prognosis.Medicine composite for curing stable phase of chronic obstructive pulmonary disease Be very effective of the present invention and having no side effect.
Detailed description of the invention
Below by specific embodiment, the present invention is described in detail; but the purposes of these exemplary embodiments and object are only used for exemplifying the present invention; not any type of any restriction is formed to real protection scope of the present invention, more non-protection scope of the present invention is confined to this.
Embodiment 1
Treat a medicine for stable phase of chronic obstructive pulmonary disease, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 30 parts, Rhizoma Polygonati 20 parts, Radix Glehniae 15 parts, Radix Asteris 15 parts, Pheretima 15 parts, Flos Inulae 10 parts, Cortex Albiziae 20 parts, Radix Salviae Miltiorrhizae 15 parts, Rhizoma Chuanxiong 15 parts, Bombyx Batryticatus (parched) 10 parts, 15 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10 parts, Radix Glycyrrhizae Preparata 10 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Epimedii 15 parts, Radix Rhodiolae 20 parts.
Concrete preparation method is as follows:
1), according to described weight portion takes the Radix Astragali, decocting that Rhizoma Polygonati, Radix Glehniae, Radix Asteris, Flos Inulae, Cortex Albiziae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae Preparata, the Rhizoma Atractylodis Macrocephalae, Herba Epimedii, Radix Rhodiolae add 13 ~ 17 times of weight 2.5 ~ 3.5 hours, filter centrifugation removes slag, and is condensed into clear paste; 2), take Pheretima, the Bombyx Batryticatus (parched) of corresponding weight portion, be broken into fine powder; 3), by step 2) products therefrom and step 1) described clear paste mixs homogeneously, and obtains described medicine.Described medicine can add customary adjuvant, conveniently technique, makes tablet, capsule, powder, pill, granule, unguentum or oral liquid.
Embodiment 2
Treat a medicine for stable phase of chronic obstructive pulmonary disease, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 30 parts, Rhizoma Polygonati 20 parts, Radix Glehniae 20 parts, Radix Asteris 15 parts, Pheretima 15 parts, Flos Inulae 12 parts, Cortex Albiziae 20 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 15 parts, Bombyx Batryticatus (parched) 12 parts, 20 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 12 parts, Radix Glycyrrhizae Preparata 9 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Epimedii 20 parts, Radix Rhodiolae 20 parts.
Concrete preparation method is with embodiment 1.
Embodiment 3
Treat a medicine for stable phase of chronic obstructive pulmonary disease, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 50 parts, Rhizoma Polygonati 30 parts, Radix Glehniae 12 parts, Radix Asteris 20 parts, Pheretima 20 parts, Flos Inulae 15 parts, Cortex Albiziae 20 parts, Radix Salviae Miltiorrhizae 15 parts, Rhizoma Chuanxiong 12 parts, Bombyx Batryticatus (parched) 12 parts, 20 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 15 parts of Radix Glycyrrhizae Preparatas 12 parts, the Rhizoma Atractylodis Macrocephalae 30 parts, Herba Epimedii 12 parts, Radix Rhodiolae 20 parts.
Concrete preparation method is with embodiment 1.
Embodiment 4:
Treat a medicine for stable phase of chronic obstructive pulmonary disease, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 20 parts, Rhizoma Polygonati 15 parts, Radix Glehniae 15 parts, Radix Asteris 12 parts, Pheretima 12 parts, Flos Inulae 6 parts, Cortex Albiziae 15 parts, Radix Salviae Miltiorrhizae 10 parts, Rhizoma Chuanxiong 10 parts, Bombyx Batryticatus (parched) 6 parts, 10 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 6 parts of Radix Glycyrrhizae Preparatas 6 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Herba Epimedii 10 parts, Radix Rhodiolae 10 parts.
Concrete preparation method is with embodiment 1.
Embodiment 5:
Treat a medicine for stable phase of chronic obstructive pulmonary disease, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 40 parts, Rhizoma Polygonati 20 parts, Radix Glehniae 20 parts, Radix Asteris 12 parts, Pheretima 15 parts, Flos Inulae 9 parts, Cortex Albiziae 18 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 15 parts, Bombyx Batryticatus (parched) 9 parts, 20 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 12 parts of Radix Glycyrrhizae Preparatas 6 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Herba Epimedii 10 parts, Radix Rhodiolae 15 parts.
Concrete preparation method is with embodiment 1.
Embodiment 6:
Treat a medicine for stable phase of chronic obstructive pulmonary disease, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 30 parts, Rhizoma Polygonati 15 parts, Radix Glehniae 15 parts, Radix Asteris 20 parts, Pheretima 12 parts, Flos Inulae 6 parts, Cortex Albiziae 20 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 10 parts, Bombyx Batryticatus (parched) 9 parts, 15 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 9 parts, Radix Glycyrrhizae Preparata 12 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Herba Epimedii 10 parts, Radix Rhodiolae 12 parts.
Concrete preparation method is with embodiment 1.
Embodiment 7
Treat a medicine for stable phase of chronic obstructive pulmonary disease, in described pharmaceutical composition, with parts by weight, its concrete constituent content is as follows:
The Radix Astragali 50 parts, Rhizoma Polygonati 30 parts, Radix Glehniae 30 parts, Radix Asteris 20 parts, Pheretima 20 parts, Flos Inulae 15 parts, Cortex Albiziae 30 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 20 parts, Bombyx Batryticatus (parched) 12 parts, 20 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 15 parts of Radix Glycyrrhizae Preparatas 12 parts, the Rhizoma Atractylodis Macrocephalae 30 parts, Herba Epimedii 20 parts, Radix Rhodiolae 30 parts.
Concrete preparation method is with embodiment 1.
Clinical research and case:
Clinical research:
1. clinical data:
1.1 physical data: 120 routine COPD stable phase patients all derive from 2012.03 ~ 2014.02 the court's Respiratory Medicines and department of Chinese medicine outpatient service, are divided into treatment group 60 example and matched group 60 example by table of random number.Treatment group man 36 example, female 14 example; 51 ~ 75 years old age, average (66.6 ± 8.9) year; Wherein pulmonary function classification I level 26 example, II level 22 example, III level 12 example; Matched group man 23 example, female 18 example; 46 ~ 73 years old age, average (65.9 ± 9.5) year; Wherein I level 25 example, II level 24 example, III level 11 example.Two groups of physical data compare, and no significant difference, has comparability.
1.2 diagnostic criteria: the related standards in " chronic obstructive pulmonary disease diagnosis and treatment specification (version in 2011) " of the formulation of Ministry of Public Health Department of Medical Administration is pressed in COPD diagnostic criteria.TCM Syndrome Type standard is with reference to Fei Xibing Professional Committee of internal medicine branch of China Association of Traditional Chinese Medicine " chronic obstructive pulmonary disease Chinese traditional medical diagnose guide (version in 2011) ".
1.3 inclusive criterias: 1. meet the diagnostic criteria of COPD stable phase; 2. pulmonary function is classified as I ~ III level; 3. Chinese medical discrimination meets asthenia of pulmonosplenic qi or insufficiency of QI of the lung and kidney, has the card of the turbid or blood stasis of expectorant concurrently; 4. 45 ~ 75 years old age; 5. the Non Apparent Abnormality such as routine blood test, routine urinalysis, liver function, renal function, electrocardiogram, rabat shows chronic bronchitis, emphysema; 6. know the inside story and agree to participate in.
1.4 exclusion standards:
1. tuberculosis, fungus, tumor etc. and other pulmonary's primary diseases are associated with; 2. pulmonary function is classified as IV level; 3. other diseases is merged as sick in Complicated with Severes such as cardiovascular, urinary system, digestion, hemopoietic, endocrine metabolism systems; 4. psychotic.
2. method:
2.1 Therapeutic Method:
Two groups are all taken the circumstances into consideration to reduce phlegm (bromhexine), spasmolytic relievings asthma the conventional therapy such as (aminophylline), nutritional support, and carry out health guidance, are 24 weeks the course for the treatment of.Matched group gives Cebo-Caps; Treatment group gives to use pharmaceutical composition of the present invention, according to embodiment 1, conveniently technique, and the capsule made.Prescription is as follows:
Radix Astragali 30g, Rhizoma Polygonati 20g, Radix Glehniae 15g, Radix Asteris 15g, Pheretima 15g, Flos Inulae 10g, Cortex Albiziae 20g, Radix Salviae Miltiorrhizae 15g, Rhizoma Chuanxiong 15g, Bombyx Batryticatus (parched) 10g, Poria 15g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10g, Radix Glycyrrhizae Preparata 10g, Rhizoma Atractylodis Macrocephalae 20g, Herba Epimedii 15g, Radix Rhodiolae 20g.
Consumption is equivalent to every day 1 dose, sooner or later divides and takes for 2 times.
2.2 observation index:
1. Evaluation on quality of life: quality of life application St george's respiratory questionnaire (SGRQ) methods of marking is evaluated.SGRQ comprises three parts, 50 road problems: respiratory symptom (cough, expectoration, asthmatic attack etc.), limitation of activity (climb, wear the clothes, play, housework etc.), sickness influence (anxiety, misery, insecurity, disappointment etc.).Pulmonary function test the same day application form by patient's complete independently, do not allow to remind with making any hint, and checked whether omission by observer.Methods of marking: the computer software applying the SGRQ Chinese edition researched and developed by BJ Union Hospital's Respiratory Medicine is evaluated.Score range is 0 ~ 100, and score value is lower, and to represent the health status of COPD patient better.
2. lung function: measure the lung function index that all patient treatments are forward and backward.Do 4 secondary peak flow rate detection every day.Expiration peak velocity (PEF) the value change that more all patient treatments are forward and backward.
3. blood gas analysis measures: measure the blood gas analysis index that all patient treatments are forward and backward.
4. exercise tolerance adopts and steps on building exercise test and detect.
5. evaluation of clinical curative effect index: effective: after treatments period and the course for the treatment of terminate, recent COPD no longer recurs; Effective: after treatments period and the course for the treatment of terminate, COPD attack times comparatively treats front minimizing, and the course for the treatment of shortens; Invalid: after treatments period and the course for the treatment of terminate, COPD attack times does not reduce, and during outbreak, its degree does not also alleviate.
6. safety index: have a blood test before and after treatment routine, routine urinalysis, liver function, renal function, electrocardiogram etc.
3. statistical procedures:
All statistical procedures all adopt SPSS10.0 statistics software to carry out.Measurement data with represent, adopt t inspection; Ranked data adopt Ridit to analyze.
4. result:
Pulmonary function and climacteric measurement of rate of flow result (see table 1) before and after 4.1 liang of group treatments
After treatment group treatment, pulmonary function indices is improved, and has significance (P < 0.05 or P < 0.01) with comparing difference before treatment; And be significantly higher than matched group (P < 0.05 or P < 0.01).Treatment group pulmonary function significantly improves.
4.2 blood gas analysis measure (see table 1)
PaO after treatment group treatment 2compare raising with before treatment, have significant difference (P < 0.01); And be significantly higher than matched group (P < 0.05 or P < 0.01).There was no significant difference (P > 0.05) is compared before and after treatment of control group.Treatment group PaO2 significantly improves.
4.3 exercise tolerances (stepping on building exercise test)
Than average many next levels before treatment after treatment group treatment, but without obviously changing before and after treatment of control group.Treatment group exercise tolerance improves.
Before and after the treatment of table 1. liang group blood gas analysis, pulmonary function and climacteric velocity ratio comparatively ( n=60)
Note: with this group before treatment Δp < 0.05, Δ Δp < 0.01; Compare with after treatment of control group *p < 0.05, *p < 0.01; Following table is same.
4.4 quality of lifes (SGRQ) scoring (see table 2)
After treatment group treatment, each item rating of SGRQ is more all improved with before treatment, has significant difference (P < 0.05 or P < 0.01); And be significantly higher than matched group (P < 0.05 or P < 0.01).There was no significant difference (P > 0.05) is compared before and after treatment of control group.Treatment group quality of life is significantly higher than matched group.
A table 2. liang group treatment front and back SGRQ scoring is compared ( n=60)
4.5 liang of groups Clinical efficacy comparison (table 3)
Effective 20 examples for the treatment of group, effective 34 examples, invalid 6 examples, total effective rate 90%; Effective 5 examples of matched group, effective 31 examples, invalid 24 examples, total effective rate 60%.Two groups are compared and have significant difference (P < 0.01), and treatment group effective percentage is apparently higher than matched group.
Table 3. liang group Clinical efficacy comparison (n=60 example)
4.6 toxic and side effects: without obviously changing before and after two groups of treatments such as hepatic and renal function, electrocardiogram, do not occur exception.
Conclusion: pharmaceutical composition of the present invention can improve the PaO2 of COPD stable phase patient, increases Activity Endurance, improves its independent living ability, improve the quality of living, improve pulmonary function.To the improvement of residual gas function, there is significance, COPD stable phase patients acuity attack times can be reduced again.Have no side effect.
Case:
Case 1:
Hao so-and-so, man, 59 years old, on November 15th, 2011 go to a doctor, make a definite diagnosis chronic bronchitis 30 years, make a definite diagnosis COPD 10 years, do not merge pulmonary heart disease.Symptom is shown in recurrent cough, expectoration, pants, dyspnea, sometimes cardiopalmus after movable.Existing symptoms including cough, pants, breathes hard, dynamic then increase the weight of, and it is few that white amount of expectoration is coughed up in cough, indigestion and loss of appetite, weak, easy catching a cold, Mental fatigue, lack of appetite, distension and fullness in the abdomen, loose stool, spontaneous perspiration, aversion to wind, corpulent tongue greatly, indentation, pale tongue, tongue fur is white.Deep and weak pulse.Be diagnosed as chronic obstructive pulmonary disease (II level, stable phase).Chinese medical discrimination: asthenia of pulmonosplenic qi, has expectorant concurrently turbid.
Prescription: Radix Astragali 50g, Rhizoma Polygonati 30g, Radix Glehniae 12g, Radix Asteris 20g, Pheretima 20g, Flos Inulae 15g, Cortex Albiziae 209, Radix Salviae Miltiorrhizae 15g, Rhizoma Chuanxiong 12g, Bombyx Batryticatus (parched) 12g, Poria 20g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 15g Radix Glycyrrhizae Preparata 12g, Rhizoma Atractylodis Macrocephalae 30g, Herba Epimedii 12g, Radix Rhodiolae 20g.Be more than the dosage of every day.Above-mentioned prescription makes granule according to embodiment 3.Every day 3 times, each 1 bag, boiled water is taken after mixing it with water.Take 24 weeks altogether.
Therapeutic outcome: the symptoms such as patient coughs, cough up phlegm, weak all comparatively before obviously alleviate, times of common cold obviously reduces, and diet increases, and without obvious abdominal distention, stool is normal.Before and after treatment, pulmonary function test and SGRQ Inventory score all significantly improve, and the results are shown in Table 4:
Table 4: Hao so-and-so treat front and back pulmonary function test result and SGRQ Inventory score
Project Before treatment After treatment
FEV1(L) 1.25 1.34
FEV1％ 51 53
FVC(L) 2.43 2.53
RV(L) 8.46 6.02
TLC(L) 11.2 8.44
FRC(L) 9.1 6.76
RV/TLC(％) 76 71
FEF25(L/sec) 1.42 1.46
FEF75(L/sec) 0.27 0.29
FEF25-75(L/sec) 0.55 0.65
FEF Max(L/sec) 3.28 3.39
VC(L) 2.74 2.42
IC(L) 2.1 1.68
Respiratory symptom 22.28 20.36
Limitation of activity 16.12 15.08
Sickness influence 10.76 8.22
SGRQ total score 49.16 43.66
PaO2(mmHg) 70.25 84.98
Case 2:
Lee so-and-so, man, 75 years old, on March 16th, 2012 went to a doctor, and makes a definite diagnosis chronic bronchitis 40 years, makes a definite diagnosis COPD 10 years, merged pulmonary heart disease 5 years.Symptom is shown in recurrent cough, expectoration, pants, dyspnea, sometimes cardiopalmus after movable.Existing disease is seen: pant, breathe hard, dynamic then increase the weight of, Mental fatigue, weak, soreness of the waist and knees, easy catching a cold, aversion to wind, and spontaneous perspiration is uncomfortable in chest, sleep poor, frequent urination at night, cyanosis of the lips and nails, and greatly, dark tongue quality has petechia to corpulent tongue, tongue fur in vain, deep and weak pulse.Be diagnosed as chronic obstructive pulmonary disease (III level, stable phase), pulmonary heart disease.Chinese medical discrimination: insufficiency of QI of the lung and kidney, has blood stasis concurrently.
Prescription: Radix Astragali 30g, Rhizoma Polygonati 20g, Radix Glehniae 20g, Radix Asteris 15g, Pheretima 15g, Flos Inulae 12g, Cortex Albiziae 20g, Radix Salviae Miltiorrhizae 20g, Rhizoma Chuanxiong 15g, Bombyx Batryticatus (parched) 12g, Poria 20g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 12g Radix Glycyrrhizae Preparata 9g, Rhizoma Atractylodis Macrocephalae 20g, Herba Epimedii 20g, Radix Rhodiolae 20g.
Be more than the dosage of every day.Above-mentioned prescription makes capsule according to embodiment 2.Every day 3 times, each 5, boiled water is taken after mixing it with water.Take 24 weeks altogether.
Therapeutic outcome: the symptoms such as patient coughs, cough up phlegm, weak, spontaneous perspiration all comparatively before obviously alleviate, times of common cold obviously reduces, and without the obvious soreness of waist, sleep takes a turn for the better, and nocturia reduces, and lip is slightly blue or green, and corpulent tongue is large, and dimly pale tongue is without obvious petechia, and tongue fur is white, deep and weak pulse.Before and after treatment, pulmonary function test and SGRQ Inventory score all significantly improve, and the results are shown in Table 5:
Table 5: Lee so-and-so treat front and back pulmonary function test result and SGRQ Inventory score
Project Before treatment After treatment
FEV1(L) 1.22 1.32
FEV1％ 47 49
FVC(L) 2.59 2.7
RV(L) 9.44 8.07
TLC(L) 12.77 11.89
FRC(L) 10.27 9.24
RV/TLC(％) 74 68
FEF25(L/sec) 1.11 1.20
FEF75(L/sec) 0.33 0.31
FEF25-75(L/sec) 0.53 0.60
FEFMax(L/sec) 3.66 3.65
VC(L) 3.33 3.82
IC(L) 2.3 2.65
Respiratory symptom 24.25 23.38
Limitation of activity 21.14 19.43
Sickness influence 14.15 11.96
SGRQ total score 59.54 54.77
PaO2(mmHg) 68.53 80.98
Case 3:
Lin, man, 70 years old, on April 6th, 2012 went to a doctor, and makes a definite diagnosis chronic bronchitis 20 years, makes a definite diagnosis COPD 10 years, merged pulmonary heart disease 5 years.Symptom is shown in recurrent cough, expectoration, pants, dyspnea, sometimes cardiopalmus after movable.Existing disease is seen: pant, breathe hard, dynamic then increase the weight of, Mental fatigue, weak, soreness of the waist and knees, easy catching a cold, aversion to wind, spontaneous perspiration, and pain uncomfortable in chest, sleeps poor, nocturia, cyanosis of the lips and nails, and corpulent tongue is large, and dark tongue quality has petechia, tongue fur in vain, deep and weak pulse.Be diagnosed as chronic obstructive pulmonary disease (III level, stable phase), pulmonary heart disease.Chinese medical discrimination: insufficiency of QI of the lung and kidney, has blood stasis concurrently.
Prescription: Radix Astragali 30g, Rhizoma Polygonati 20g, Radix Glehniae 20g, Radix Asteris 15g, Pheretima 15g, Flos Inulae
RV/TLC(％) 95 77
FEF25(L/sec) 1.11 1.56
FEF75(L/sec) 0.32 0.34
FEF25-75(L/sec) 0.57 0.57
FEF Max(L/sec) 2.77 2.95
VC(L) 2.6 1.94
IC(L) 2.13 0.21
Respiratory symptom 24.15 20.24
Limitation of activity 21.96 19.55
Sickness influence 12.56 10.76
SGRQ total score 58.67 50.55
PaO2(mmHg) 69.01 81.26
Case 4:
Dong so-and-so, man, 56 years old, on February 11st, 2013 go to a doctor, make a definite diagnosis chronic bronchitis 10 years, make a definite diagnosis COPD 2 years, do not merge pulmonary heart disease.Symptom is shown in recurrent cough, expectoration, pants, dyspnea, sometimes cardiopalmus after movable.Existing symptoms including cough, pants time movable, breathes hard, dynamic then increase the weight of, and it is few, indigestion and loss of appetite, weak that white amount of expectoration is coughed up in cough, Mental fatigue, loose stool, Chang Zihan, aversion to wind, easy catching a cold, corpulent tongue greatly, indentation, body of the tongue is light red, and tongue fur is white.Deep and weak pulse.Be diagnosed as chronic obstructive pulmonary disease (III level, stable phase).Chinese medical discrimination: asthenia of pulmonosplenic qi.
Prescription: Radix Astragali 40g, Rhizoma Polygonati 20g, Radix Glehniae 20g, Radix Asteris 12g, Pheretima 15g, Flos Inulae 9g, Cortex Albiziae 18g, Radix Salviae Miltiorrhizae 20g, Rhizoma Chuanxiong 15g, Bombyx Batryticatus (parched) 9g, Poria 20g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 12g Radix Glycyrrhizae Preparata 6g, Rhizoma Atractylodis Macrocephalae 15g, Herba Epimedii 10g, Radix Rhodiolae 15g.
Be more than the dosage of every day.Above-mentioned prescription makes granule according to embodiment 5.Every day 3 times, each 1 bag, boiled water is taken after mixing it with water.Take 24 weeks altogether.
Therapeutic outcome: the symptoms such as patient coughs, breathe hard, weak, spontaneous perspiration all comparatively before obviously alleviate, times of common cold obviously reduces, and diet increases, and stool is normal.Before and after treatment, pulmonary function test and SGRQ Inventory score all significantly improve, and the results are shown in Table 7:
Table 7: Dong so-and-so treat front and back pulmonary function test result and SGRQ Inventory score
Project Before treatment After treatment
FEV1(L) 1.01 1.39
FEV1％ 49 56
FVC(L) 2.05 2.48
RV(L) 11.84 10.69
TLC(L) 13.98 13.3
FRC(L) 12.36 11.18
RV/TLC(％) 85 80
FEF25(L/sec) 1.03 1.50
FEF75(L/sec) 0.30 0.33
FEF25-75(L/sec) 0.55 0.79
FEF Max(L/sec) 1.71 2.68
VC(L) 2.14 2.61
IC(L) 1.62 2.12
Respiratory symptom 23.16 20.28
Limitation of activity 21.46 18.25
Sickness influence 11.76 10.15
12g, Cortex Albiziae 20g, Radix Salviae Miltiorrhizae 20g, Rhizoma Chuanxiong 15g, Bombyx Batryticatus (parched) 12g, Poria 20g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 12g Radix Glycyrrhizae Preparata 9g, Rhizoma Atractylodis Macrocephalae 20g, Herba Epimedii 20g, Radix Rhodiolae 20g.
Be more than the dosage of every day.Above-mentioned prescription makes capsule according to embodiment 2.Every day 3 times, each 5, boiled water is taken after mixing it with water.Take 24 weeks altogether.
Therapeutic outcome: the symptoms such as patient coughs, cough up phlegm, weak, spontaneous perspiration all comparatively before obviously alleviate, times of common cold obviously reduces, without the obvious soreness of waist, sleep still can, nocturia reduces, and lip is slightly dark, and tongue body is slightly fat, and dark tongue quality is without obvious petechia, and tongue fur is white, deep and weak pulse.Before and after treatment, pulmonary function test and SGRQ Inventory score all significantly improve, and the results are shown in Table 6:
Table 6: pulmonary function test result and SGRQ Inventory score before and after Lin's treatment
Project Before treatment After treatment
FEV1(L) 1.05 1.19
FEV1％ 48 53
FVC(L) 2.17 2.26
RV(L) 13.91 8.55
TLC(L) 14.5 11.15
FRC(L) 12.45 10.94
SGRQ total score 56.38 48.68
PaO2(mmHg) 65.33 78.67
Case 5:
Gold so-and-so, man, 69 years old, on January 22nd, 2013 went to a doctor, and makes a definite diagnosis chronic bronchitis 11 years, makes a definite diagnosis COPD 6 years, merged pulmonary heart disease 3 years.Symptom is shown in recurrent cough, expectoration, pants, dyspnea, sometimes cardiopalmus after movable.Existing disease is seen: pant, breathe hard, dynamic then increase the weight of, Mental fatigue, weak, soreness of the waist and knees, easy catching a cold, aversion to wind, and spontaneous perspiration, sometimes pain uncomfortable in chest, sleep not good enough, anxious, frequent urination at night, and lip and nail color is dark, and corpulent tongue is large, dimly pale tongue, tongue fur in vain, deep and weak pulse.Be diagnosed as chronic obstructive pulmonary disease (III level, stable phase), pulmonary heart disease.Chinese medical discrimination: insufficiency of QI of the lung and kidney, has blood stasis concurrently.
Prescription: Radix Astragali 30g, Rhizoma Polygonati 20g, Radix Glehniae 15g, Radix Asteris 15g, Pheretima 15g, Flos Inulae 10g, Cortex Albiziae 20g, Radix Salviae Miltiorrhizae 15g, Rhizoma Chuanxiong 15g, Bombyx Batryticatus (parched) 10g, Poria 15g, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10g, Radix Glycyrrhizae Preparata 10g, Rhizoma Atractylodis Macrocephalae 20g, Herba Epimedii 15g, Radix Rhodiolae 20g.
Be more than the dosage of every day.Above-mentioned prescription makes capsule according to embodiment 1.Every day 3 times, each 5, boiled water is taken after mixing it with water.Take 24 weeks altogether.
Therapeutic outcome: the symptoms such as patient coughs, cough up phlegm, weak, spontaneous perspiration all comparatively before obviously alleviate, times of common cold obviously reduces, and without the obvious soreness of waist, sleep takes a turn for the better, and nocturia reduces, and lip is slightly blue or green, and corpulent tongue is large, and dimly pale tongue is without obvious petechia, and tongue fur is white, deep and weak pulse.Before and after treatment, pulmonary function test and SGRQ Inventory score all significantly improve, and the results are shown in Table 8:
Table 8: golden so-and-so treats front and back pulmonary function test result and SGRQ Inventory score
Project Before treatment After treatment
FEV1(L) 1.03 1.22
FEV1％ 45 51
FVC(L) 2.29 2.41
RV(L) 6.4 8.87
TLC(L) 9.01 11.23
FRC(L) 7.24 9.08
RV/TLC(％) 71 79
FEF25(L/sec) 1.01 1.24
FEF75(L/sec) 0.24 0.43
FEF25-75(L/sec) 0.45 0.73
FEF Max(L/sec) 2.39 3.37
VC(L) 2.61 2.35
IC(L) 1.77 2.15
Respiratory symptom 28.79 21.18
Limitation of activity 21.14 17.14
Sickness influence 9.26 7.22
SGRQ total score 59.19 45.54
PaO2(mmHg) 62.65 75.56

Claims (6)

1. treat a medicine for stable phase of chronic obstructive pulmonary disease, it is characterized in that: described medicine comprises the Radix Astragali, Rhizoma Polygonati, Radix Glehniae, Radix Asteris, Pheretima, Flos Inulae, Cortex Albiziae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Bombyx Batryticatus (parched), Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae Preparata, the Rhizoma Atractylodis Macrocephalae, Herba Epimedii and Radix Rhodiolae.
2. a kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease as claimed in claim 1, it is characterized in that, each component of described medicine according to parts by weight is: Radix Astragali 20-50 part, Rhizoma Polygonati 15-30 part, Radix Glehniae 15-30 part, Radix Asteris 12-20 part, Pheretima 12-20 part, Flos Inulae 6-15 part, Cortex Albiziae 15-30 part, Radix Salviae Miltiorrhizae 10-20 part, Rhizoma Chuanxiong 10-20 part, Bombyx Batryticatus (parched) 6-12 part, Poria 10-20 part, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 6-15 part Radix Glycyrrhizae Preparata 6-12 part, Rhizoma Atractylodis Macrocephalae 10-30 part, Herba Epimedii 10-20 part, Radix Rhodiolae 10-30 part.
3. a kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease as claimed in claim 1 or 2, it is characterized in that, each component of described medicine according to parts by weight is: the Radix Astragali 30 parts, Rhizoma Polygonati 20 parts, Radix Glehniae 15 parts, Radix Asteris 15 parts, Pheretima 15 parts, Flos Inulae 10 parts, Cortex Albiziae 20 parts, Radix Salviae Miltiorrhizae 15 parts, Rhizoma Chuanxiong 15 parts, Bombyx Batryticatus (parched) 10 parts, 15 parts, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) 10 parts, Radix Glycyrrhizae Preparata 10 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Epimedii 15 parts, Radix Rhodiolae 20 parts.
4. a kind of medicine for the treatment of stable phase of chronic obstructive pulmonary disease as claimed in claim 1, its preparation method is: 1), according to described weight portion took the Radix Astragali, Rhizoma Polygonati, Radix Glehniae, Radix Asteris, Flos Inulae, Cortex Albiziae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Poria, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Glycyrrhizae Preparata, the Rhizoma Atractylodis Macrocephalae, Herba Epimedii, Radix Rhodiolae clear water immersion 2 as a child, add the decocting 2.5 ~ 3.5 hours of 13 ~ 17 times of weight, filter centrifugation removes slag, and is condensed into clear paste; 2), take Pheretima, the Bombyx Batryticatus (parched) of corresponding weight portion, be broken into fine powder; 3), by step 2) gained fine powder uniform stirring in, obtain described medicine.
5. process for preparing medicine as claimed in claim 4, is characterized in that: described step 1) for adding the decocting 3 hours of 15 times of weight.
6. process for preparing medicine as claimed in claim 4, is characterized in that: described medicine is tablet, capsule, powder, pill, granule, unguentum or oral liquid.
CN201510000466.6A 2015-01-04 2015-01-04 Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine Pending CN104491415A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510000466.6A CN104491415A (en) 2015-01-04 2015-01-04 Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510000466.6A CN104491415A (en) 2015-01-04 2015-01-04 Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine

Publications (1)

Publication Number Publication Date
CN104491415A true CN104491415A (en) 2015-04-08

Family

ID=52932929

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510000466.6A Pending CN104491415A (en) 2015-01-04 2015-01-04 Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine

Country Status (1)

Country Link
CN (1) CN104491415A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104815262A (en) * 2015-04-12 2015-08-05 杨善兰 Chinese herbal preparation for treating early chronic obstructive pulmonary disease in stable stage
CN105727031A (en) * 2016-03-30 2016-07-06 赵瑜飞 Formula of LouBeiZhiJuMuGen decoction for treating chronic obstructive pulmonary disease
CN105770398A (en) * 2016-04-11 2016-07-20 吴金霞 Cough suppression drink with rhodiola sachalinensis
CN105796885A (en) * 2016-04-28 2016-07-27 田志英 Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease
CN106039156A (en) * 2016-06-06 2016-10-26 宋义清 Traditional Chinese medicine for treating chronic obstructive pulmonary disease in stable stage
CN109771632A (en) * 2019-03-29 2019-05-21 成都中医药大学附属医院 A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease
CN111184812A (en) * 2020-01-21 2020-05-22 金华市中心医院 Application of compound stachys sieboldii particle chronic obstructive pulmonary disease treatment pharmaceutical preparation
CN111821408A (en) * 2020-07-31 2020-10-27 河南中医药大学 Traditional Chinese medicine formula for treating pneumoconiosis lung qi deficiency syndrome and lung and kidney qi deficiency syndrome and application thereof
CN114392322A (en) * 2022-03-07 2022-04-26 中国中医科学院中药研究所 Traditional Chinese medicine granule and preparation method and application thereof
CN115025174A (en) * 2022-06-28 2022-09-09 杨永华 Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102258688A (en) * 2011-07-21 2011-11-30 河南中医学院 Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102258688A (en) * 2011-07-21 2011-11-30 河南中医学院 Traditional Chinese medicine for treating lung-spleen qi deficiency syndrome of chronic obstructive pulmonary disease (COPD)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
中华中医药学会内科分会肺系病专业委员会: "慢性阻塞性肺疾病中医诊疗指南（2011版）", 《中医杂志》 *
吴起相: "慢性阻塞性肺疾病的中医辨治体会", 《中国中医急症》 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104815262A (en) * 2015-04-12 2015-08-05 杨善兰 Chinese herbal preparation for treating early chronic obstructive pulmonary disease in stable stage
CN105727031A (en) * 2016-03-30 2016-07-06 赵瑜飞 Formula of LouBeiZhiJuMuGen decoction for treating chronic obstructive pulmonary disease
CN105770398A (en) * 2016-04-11 2016-07-20 吴金霞 Cough suppression drink with rhodiola sachalinensis
CN105796885A (en) * 2016-04-28 2016-07-27 田志英 Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease
CN106039156A (en) * 2016-06-06 2016-10-26 宋义清 Traditional Chinese medicine for treating chronic obstructive pulmonary disease in stable stage
CN109771632B (en) * 2019-03-29 2021-09-03 成都中医药大学附属医院 Pharmaceutical composition for treating chronic obstructive pulmonary disease in stable phase and preparation method and application thereof
CN109771632A (en) * 2019-03-29 2019-05-21 成都中医药大学附属医院 A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease
CN111184812A (en) * 2020-01-21 2020-05-22 金华市中心医院 Application of compound stachys sieboldii particle chronic obstructive pulmonary disease treatment pharmaceutical preparation
CN111184812B (en) * 2020-01-21 2021-08-20 金华市中心医院 Application of compound stachys sieboldii particle chronic obstructive pulmonary disease treatment pharmaceutical preparation
CN111821408A (en) * 2020-07-31 2020-10-27 河南中医药大学 Traditional Chinese medicine formula for treating pneumoconiosis lung qi deficiency syndrome and lung and kidney qi deficiency syndrome and application thereof
CN111821408B (en) * 2020-07-31 2023-01-24 河南中医药大学 Traditional Chinese medicine composition for treating pneumoconiosis lung qi deficiency syndrome and lung and kidney qi deficiency syndrome and application thereof
CN114392322A (en) * 2022-03-07 2022-04-26 中国中医科学院中药研究所 Traditional Chinese medicine granule and preparation method and application thereof
CN115025174A (en) * 2022-06-28 2022-09-09 杨永华 Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof
CN115025174B (en) * 2022-06-28 2023-06-02 杨永华 A Chinese medicinal composition for treating chronic obstructive pulmonary disease, and its preparation method

Similar Documents

Publication Publication Date Title
CN104491415A (en) Medicine for treating chronic obstructive pulmonary disease during stable period and preparation method of medicine
CN101658631A (en) Drug for treating chronic bronchitis and pulmonary emphysema
CN103520413A (en) Chinese medicament for treating asthma
CN103463568A (en) Traditional Chinese medicine for treating coronary heart disease
CN102949630B (en) Traditional Chinese medicine composition for treating abdominal distension caused by lack of gastrointestinal motility
CN105311219A (en) Health Jieyu Ningshen mixture
CN103919906A (en) Traditional Chinese medicine composition for treating hypermenorrhea
CN111467459B (en) Traditional Chinese medicine composition for treating novel coronavirus pneumonia at recovery stage, application and preparation method thereof
CN102085346A (en) Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease
CN102188689B (en) Compound combination medicament for treating COPD, preparation method and application thereof
CN106075374A (en) Cough relief traditional Chinese medicine for treating winter disease in summer
CN107802774A (en) Chinese medicine of tonifying spleen lung cough-relieving asthma and preparation method thereof
CN103800689A (en) Traditional Chinese medicine composition for treating diabetes mellitus
CN103405574B (en) Medicinal composition for treating hypertension
CN102302729B (en) Chinese medicinal preparation for treating oral aphthae during menstruation
CN106267003B (en) A kind of stilbene art anticancer traditional Chinese medicinal composition
CN109771632A (en) A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease
CN104491800A (en) Traditional Chinese medicine composition for treating chronic colitis
CN103263611A (en) Traditional Chinese medicine composition for treating colonitis
CN116763880B (en) Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation
CN103495025A (en) Traditional Chinese medicine preparation for treating pulmonary fibrosis
CN112043757B (en) Health-preserving coffee and traditional Chinese medicine composition
CN113304234B (en) Traditional Chinese medicine composition for treating chronic renal failure
CN107582834A (en) A kind of Chinese medicine composition for treating empty asthma
CN107802795B (en) Traditional Chinese medicine jaundice-removing enema for treating icteric hepatitis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150408